Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation

Bibliography

• Stehlik J, Edwards LB, Kucheryavaya AY, The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Heart Transplant Report–2011. J Heart Lung Transplant 2011;30:1078-94
   PubMed Web of Science ®Google Scholar
• Suzuki J, Isobe M, Morishita R, Characteristics of chronic rejection in heart transplantation –Important elements of pathogenesis and future treatments. Circ J 2010;74:233-9
   PubMed Web of Science ®Google Scholar
• Suzuki J, Isobe M, Aikawa M, Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 1996;94:1118-24
   Google Scholar
• Mitchell RN. Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol 2009;4:19-47
   PubMed Web of Science ®Google Scholar
• Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008;117:2131-41
   PubMed Web of Science ®Google Scholar
• Ramzy D, Rao V, Brahm J, Cardiac allograft vasculopathy: a review. Can J Surg 2005;48:319-27
   PubMed Web of Science ®Google Scholar
• Mitchell R, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007;100:967-78
   PubMed Web of Science ®Google Scholar
• Libby P, Pober J. Chronic rejection. Immunity 2001;14:387-97
   PubMed Web of Science ®Google Scholar
• Szczech LA, Feldman HI. Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Transplant Proc 1999;31:9S-11S
   PubMed Web of Science ®Google Scholar
• Schnitzler M, Hasskarl J, Egger M, Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910-18
   PubMed Web of Science ®Google Scholar
• Hanaway MJ, Woodle ES, Mulgaonkar S, Alemtuzumab induction in renal transplantation. N Engl J Med 2011;364:1909-19
   PubMed Web of Science ®Google Scholar
• Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 2007;26:750-2
   PubMed Web of Science ®Google Scholar
• Teuteberg JJ, Shullo MA, Zomak R, Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010;10:382-8
   PubMed Web of Science ®Google Scholar
• Isobe M, Yagita H, Okumura K, Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992;255:1125-7
   PubMed Web of Science ®Google Scholar
• Isobe M, Suzuki J, Yamazaki S, Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 1997;96:2247-53
   PubMed Web of Science ®Google Scholar
• Isobe M, Suzuki J, Yamazaki S, Assessment of tolerance induction to cardiac allograft by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. J Heart Lung Transplant 1997;16:1149-56
   Google Scholar
• Suzuki J, Isobe M, Yamazaki S, Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant 1997;16:1141-8
   Google Scholar
• Mauri DN, Ebner R, Montgomery RI, LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000;6:283-9
   PubMedGoogle Scholar
• Tamada K, Shimozaki K, Chapoval AI, LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000;164:4105-10
   PubMed Web of Science ®Google Scholar
• Marsters SA, Ayres TM, Skubatch M, Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997;272:14029-32
   PubMed Web of Science ®Google Scholar
• Ye Q, Fraser CC, Gao W, Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002;195:795-800
   Google Scholar
• Kosuge H, Suzuki J, Kakuta T, Attenuation of graft arterial disease by manipulation of the LIGHT pathway. Arterioscler Thromb Vasc Biol 2004;24:1409-15
   PubMedGoogle Scholar
• Ishida Y, Agata Y, Shibahara K, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-95
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72
   PubMed Web of Science ®Google Scholar
• Vibhakar R, Juan G, Traganos F, Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res 1997;232:25-8
   PubMed Web of Science ®Google Scholar
• Okazaki T, Maeda A, Nishimura H, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001;98:13866-71
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538-45
   PubMed Web of Science ®Google Scholar
• Ozkaynak E, Wang L, Goodearl A, Programmed death-1 targeting can promote allograft survival. J Immunol 2002;169:6546-53
   PubMed Web of Science ®Google Scholar
• Koga N, Suzuki J, Kosuge H, The blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004;24:2057-62
   PubMed Web of Science ®Google Scholar
• Hutloff A, Dittrich AM, Beier KC, ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-6
   PubMed Web of Science ®Google Scholar
• Yoshinaga SK, Whoriskey JS, Khare SD, T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827-32
   PubMed Web of Science ®Google Scholar
• Ozkaynak E, Gao W, Shemmeri N, Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001;2:591-6
   PubMed Web of Science ®Google Scholar
• Kosuge H, Suzuki J, Haraguchi G, Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2660-5
   Google Scholar
• Russell ME, Hancock WW, Akalin E, Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996;97:833-8
   Google Scholar
• Onodera K, Chandraker A, Schaub M, CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol 1997;159:1711-17
   Google Scholar
• Raisanen-Sokolowski A, Glysing-Jensen T, Mottram PL, Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allografts. Arterioscler Thromb Vasc Biol 1997;17:2115-22
   Google Scholar
• Shimizu K, Schonbeck U, Mach F, Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000;165:3506-18
   Google Scholar
• Wang CY, Mazer SP, Minamoto K, Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation 2002;105:1609-14
   Google Scholar
• Nykanen AI, Sandelin H, Krebs R, Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010;121:1413-22
   Google Scholar
• Booth AJ, Csencsits-Smith K, Wood SC, Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010;10:220-30
   PubMed Web of Science ®Google Scholar
• Diaz JA, Booth AJ, Lu G, Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009;9:1773-83
   Google Scholar
• Kitamura S, Nakatani T, Kato T, Hemodynamic and echocardiographic evaluation of orthotopic heart transplantation with the modified bicaval anastomosis technique. Circ J 2009;73:1235-9
   Google Scholar